Co-Diagnostics, Inc. (NASDAQ: CODX) announced today that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia. The new territory includes Bangladesh, Pakistan, Nepal, and Sri Lanka, significantly increasing the company's addressable market to an estimated $13.0 billion.
The expansion supports the planned commercialization of the CoSara PCR Pro(R) point-of-care platform and the SARAGENE(R) product line, subject to regulatory approvals. As the company builds regional distribution channels, it positions itself for broader deployment of its molecular diagnostics solutions across the expanded region.
According to the press release, this move is a strategic step for Co-Diagnostics as it seeks to penetrate underserved markets in South Asia. The company's proprietary technologies are utilized for tests designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). Co-Diagnostics also uses its technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform, which is subject to regulatory review and not currently for sale, and to identify genetic markers for applications other than infectious disease.
Co-Diagnostics, Inc., a Utah corporation, develops, manufactures, and markets state-of-the-art diagnostics technologies. The company's joint venture, CoSara Diagnostics Pvt. Ltd., is based in India and focuses on molecular diagnostics. For more information about Co-Diagnostics, visit https://co-dx.com/.
The full press release can be viewed at https://ibn.fm/2aATV.
This expansion is significant as it opens up new markets for Co-Diagnostics' innovative diagnostic solutions, potentially improving access to molecular diagnostics in regions with high disease burden. The increased addressable market of $13 billion underscores the commercial potential of this move.
